Key result
CaMKII inhibition suppresses arrhythmogenic Ca2+ release but promotes Ca2+ alternans by prolonging release refractoriness in ventricular cardiomyocytes with a gain-of-function RyR2 mutation.
Why the study?
Does CaMKII inhibition affect spontaneous Ca2+ release and Ca2+ alternans in ventricular cardiomyocytes from mice with a gain-of-function RyR2 mutation?
Does CaMKII inhibition affect spontaneous Ca2+ release and Ca2+ alternans in ventricular cardiomyocytes from mice with a gain-of-function RyR2 mutation?
In a mouse model of RyR2 gain-of-function, CaMKII inhibition demonstrates dual effects by suppressing spontaneous Ca2+ release but promoting arrhythmogenic Ca2+ alternans.
CaMKII inhibition may promote alternans despite suppressing spontaneous release; leaves open net antiarrhythmic effect in RyR2-mutant models.
Genetically increased RyR2 activity promotes arrhythmogenic Ca 2+ release. Inhibition of CaMKII suppresses RyR2 activity and arrhythmogenic Ca 2+ release. Suppression of RyR2 activity prolongs refractoriness of Ca 2+ release. Prolonged refractoriness of Ca 2+ release leads to arrhythmogenic Ca 2+ alternans. CaMKII inhibition promotes Ca 2+ alternans by prolonging Ca 2+ release refractoriness.
No takes yet. Share an insight, caveat, or question.
Sadredini et al. (2021) studied this question. CaMKII inhibition suppresses arrhythmogenic Ca2+ release but promotes Ca2+ alternans by prolonging release refractoriness in ventricular cardiomyocytes with a gain-of-function RyR2 mutation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: